In addition, an increased invasion capability, epithelial–mesenchymal transition markers expression, and sensitivity to doxorubicin in silenced TRPML2 and a shorter OS in TRPML2 overexpressing GBM patients was reported [19]. The gene discussed is MCOLN2; the disease is glioblastoma.